SALT LAKE CITY, April 29, 2021 /PRNewswire/
-- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"),
a molecular diagnostics company with a unique, patented platform
for the development of diagnostic tests, announced today that it
will be accompanying Dr. Heather
Fehling, Chief Scientific Officer at Clinical Reference Lab
("CRL") in a webinar titled "A New Generation of PCR: At-home
Testing and Preparing for Emerging Strains of COVID-19" on
Thursday, April 29 at 2:00 PM EDT.
The 360Dx webinar is expected to provide insights regarding
future applications of PCR testing for COVID-19, how CRL is able to
provide non-invasive and highly accurate saliva PCR tests for
at-home collection, and how new PCR science and technology is
enabling and expanding the applications and accessibility of PCR
tests. Co-Diagnostics Senior Design Engineer Masen Christensen will discuss the results of
ongoing monitoring and analyses of emerging COVID-19 mutations as
they relate to the technology's performance.
In November, CRL announced that it is selling its CRL Rapid
Response saliva-based COVID-19 RT-PCR test directly to consumers.
The CRL announcement states that the test uses CoPrimer™ probes and
primers developed by Co-Diagnostics with high degrees of
sensitivity and specificity, and a simple saliva collection device
that can be administered in virtually any setting, with results in
typically 24 hours that are delivered via a secure online computer
or mobile device platform.
Interested participants in the webinar can register here.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah
corporation, is a molecular diagnostics company that develops,
manufactures and markets a new, state-of-the-art diagnostics
technology. The Company's technology is utilized for tests that are
designed using the detection and/or analysis of nucleic acid
molecules (DNA or RNA). The Company also uses its proprietary
technology to design specific tests to locate genetic markers for
use in industries other than infectious disease and license the use
of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements
in this release include statements regarding the (i) use of funding
proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company's liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company's
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company's balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to rely
on any forward-looking statements. Any forward-looking statement
made by the Company in this press release is based only on
information currently available to the Company and speaks only as
of the date on which it is made. The Company does not undertake any
obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-and-partner-crl-to-discuss-saliva-testing-and-future-applications-of-pcr-in-360dx-webinar-301280326.html
SOURCE Co-Diagnostics